![Dikla Berko-Ashur](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Dikla Berko-Ashur
Sociétés | Poste | Début | Fin |
---|---|---|---|
Sakura Bio
![]() Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Directeur Général | 01/10/2022 | - |
Fondateur | 01/10/2022 | - |
Historique de carrière de Dikla Berko-Ashur
Statistiques
Internationale
Israël | 2 |
Opérationnelle
Chief Executive Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Sakura Bio
![]() Sakura Bio BiotechnologyHealth Technology Sakura Bio is a start-up company based in Jerusalem, Israel. Sakura Bio is developing an off-the-shelf, allogeneic T-cell therapy to fight cancer. The Israeli company's lead product, SAK-T (Super Activated Killer T-cell), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. The company was founded by Dikla Berko-Ashur and Amnon Peled, with Dikla Berko-Ashur serving as CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Dikla Berko-Ashur
- Expérience